| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.71▲ | 1.71▲ | 1.71▲ | 1.67▲ | 1.64▲ |
| MA10 | 1.70▲ | 1.70▲ | 1.71▲ | 1.61▲ | 1.62▲ |
| MA20 | 1.71▲ | 1.71▲ | 1.68▲ | 1.61▲ | 1.53▲ |
| MA50 | 1.71▲ | 1.66▲ | 1.62▲ | 1.62▲ | 1.85▼ |
| MA100 | 1.71▲ | 1.61▲ | 1.63▲ | 1.50▲ | 5.39▼ |
| MA200 | 1.67▲ | 1.63▲ | 1.58▲ | 1.61▲ | 16.16▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.003▲ | -0.002▼ | 0.000▼ | 0.012▲ | 0.068▲ |
| RSI | 66.114▲ | 61.219▲ | 63.937▲ | 58.110▲ | 50.778▲ |
| STOCH | 58.333 | 41.419 | 20.098 | 55.175 | 42.449 |
| WILL %R | 0.000▲ | -60.714 | -50.000 | -34.286 | -44.595 |
| CCI | 141.728▲ | 33.903 | 61.818 | 118.626▲ | 73.996 |
|
Monday, October 13, 2025 01:24 PM
Presentations feature data from first-in-human Phase 1 study including Cyclin E1 biomarker findings, supporting late-stage development of azenosertibSAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- ...
|
|
Wednesday, October 08, 2025 09:05 AM
Premarket trading on Wednesday showed a generally upbeat tone, reflecting a modest rebound after the previous day’s declines. On the New York Stock Exchange (NYSE), about 65% of listed stocks (1,190) ...
|
|
Wednesday, October 01, 2025 03:20 PM
SAN DIEGO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 27/10/25 | 1.715 | 1.815 | 1.67 | 1.72 | 426,021 |
| 24/10/25 | 1.68 | 1.725 | 1.64 | 1.71 | 484,400 |
| 23/10/25 | 1.63 | 1.65 | 1.61 | 1.64 | 375,137 |
| 22/10/25 | 1.60 | 1.65 | 1.55 | 1.63 | 693,800 |
| 21/10/25 | 1.57 | 1.67 | 1.53 | 1.64 | 905,969 |
| 20/10/25 | 1.52 | 1.58 | 1.502 | 1.55 | 536,959 |
| 17/10/25 | 1.54 | 1.57 | 1.49 | 1.49 | 799,527 |
| 16/10/25 | 1.62 | 1.69 | 1.53 | 1.56 | 831,800 |
| 15/10/25 | 1.56 | 1.65 | 1.54 | 1.59 | 1,436,566 |
| 14/10/25 | 1.60 | 1.63 | 1.53 | 1.54 | 1,015,100 |
|
|
||||
|
|
||||
|
|